C Patrono

Summary

Affiliation: Catholic University
Country: Italy

Publications

  1. ncbi request reprint Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Carlo Patrono
    University of Rome La Sapienza, Via di Grottarossa 1035, 00189 Rome, Italy
    Chest 126:234S-264S. 2004
  2. doi request reprint Nonsteroidal antiinflammatory drugs: past, present and future
    Carlo Patrono
    Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
    Pharmacol Res 59:285-9. 2009
  3. doi request reprint Platelet activation and inhibition in polycythemia vera and essential thrombocythemia
    Carlo Patrono
    Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
    Blood 121:1701-11. 2013
  4. doi request reprint Aspirin, 110 years later
    C Patrono
    Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
    J Thromb Haemost 7:258-61. 2009
  5. doi request reprint Aspirin: promise and resistance in the new millennium
    Carlo Patrono
    Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
    Arterioscler Thromb Vasc Biol 28:s25-32. 2008
  6. doi request reprint The future of antiplatelet therapy in cardiovascular disease
    Carlo Patrono
    Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
    Annu Rev Med 61:49-61. 2010
  7. doi request reprint Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Carlo Patrono
    Catholic University School of Medicine, Largo F Vito 1, Rome, Italy
    Chest 133:199S-233S. 2008
  8. doi request reprint The P2Y12 receptor: no active metabolite, no party
    Carlo Patrono
    Department of Pharmacology, Catholic University School of Medicine, Largo F Vito 1, Rome, Italy
    Nat Rev Cardiol 6:271-2. 2009
  9. doi request reprint Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges
    Carlo Patrono
    Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
    Mol Interv 9:31-9. 2009
  10. doi request reprint Antiplatelet agents for the treatment and prevention of atherothrombosis
    Carlo Patrono
    Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
    Eur Heart J 32:2922-32. 2011

Collaborators

Detail Information

Publications47

  1. ncbi request reprint Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Carlo Patrono
    University of Rome La Sapienza, Via di Grottarossa 1035, 00189 Rome, Italy
    Chest 126:234S-264S. 2004
    ....
  2. doi request reprint Nonsteroidal antiinflammatory drugs: past, present and future
    Carlo Patrono
    Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
    Pharmacol Res 59:285-9. 2009
    ....
  3. doi request reprint Platelet activation and inhibition in polycythemia vera and essential thrombocythemia
    Carlo Patrono
    Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
    Blood 121:1701-11. 2013
    ..A clear pharmacodynamic rationale and analytical tools are available for a personalized approach to antiplatelet therapy in ET, and an improved regimen of low-dose aspirin therapy should be tested in a properly sized randomized trial...
  4. doi request reprint Aspirin, 110 years later
    C Patrono
    Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
    J Thromb Haemost 7:258-61. 2009
    ..secondary prevention...
  5. doi request reprint Aspirin: promise and resistance in the new millennium
    Carlo Patrono
    Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
    Arterioscler Thromb Vasc Biol 28:s25-32. 2008
    ....
  6. doi request reprint The future of antiplatelet therapy in cardiovascular disease
    Carlo Patrono
    Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
    Annu Rev Med 61:49-61. 2010
    ..Recent advances in the pharmacogenetics of thienopyridines open the realistic prospect of a personalized choice of the most appropriate antiplatelet agent and tailored dose adjustment for an individual patient...
  7. doi request reprint Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Carlo Patrono
    Catholic University School of Medicine, Largo F Vito 1, Rome, Italy
    Chest 133:199S-233S. 2008
    ....
  8. doi request reprint The P2Y12 receptor: no active metabolite, no party
    Carlo Patrono
    Department of Pharmacology, Catholic University School of Medicine, Largo F Vito 1, Rome, Italy
    Nat Rev Cardiol 6:271-2. 2009
    ..Impaired platelet inhibition reflects inadequate plasma levels of active metabolites, and not differences in platelet P2Y12 receptor function...
  9. doi request reprint Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges
    Carlo Patrono
    Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
    Mol Interv 9:31-9. 2009
    ..In this Review, the authors offer an assessment of drug pharmacokinetics and enzyme physiology that reconciles cardiovascular appraisals from a wide array of clinical data...
  10. doi request reprint Antiplatelet agents for the treatment and prevention of atherothrombosis
    Carlo Patrono
    Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
    Eur Heart J 32:2922-32. 2011
    ....
  11. ncbi request reprint Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo
    R Landolfi
    Department of Medicine, Catholic University School of Medicine, Rome, Italy
    Blood 80:1965-71. 1992
    ..This in vivo abnormality in platelet biochemistry can be largely suppressed by low doses of aspirin...
  12. ncbi request reprint Biosynthesis and pharmacological modulation of thromboxane in humans
    C Patrono
    Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
    Circulation 81:I12-5; discussion I22-3. 1990
    ..Finally, TXA2-dependent glomerular damage, as seen in lupus nephritis, might represent a unique therapeutic target for receptor antagonists and/or tissue-selective synthase inhibitors...
  13. ncbi request reprint Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus
    R De Cristofaro
    Center of Excellence on Aging, G D Annunziou University School of Medicine and Pharmacy, Chieti, Italy
    J Thromb Haemost 1:250-6. 2003
    ..In conclusion, OS in T2DM involves circulating proteins and is associated with an unbalanced promotion of procoagulant reactions. These effects in concert with platelet activation may contribute to atherothrombotic complications in T2DM...
  14. doi request reprint The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes
    B Rocca
    Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
    J Thromb Haemost 10:1220-30. 2012
    ..We hypothesized that faster recovery of platelet cyclooxygenase-1 activity may explain incomplete thromboxane (TX) inhibition during the 24-h dosing interval...
  15. ncbi request reprint Human eicosanoid biosynthesis and metabolism
    C Patrono
    Department of Pharmacology, University of Chieti School of Medicine, Italy
    Mt Sinai J Med 59:157-62. 1992
    ..Application of the same investigative approach to other recently identified products of arachidonate metabolism (2) may provide further insight into the pathophysiologic significance of this complex mediator system...
  16. ncbi request reprint Aspirin resistance: definition, mechanisms and clinical read-outs
    C Patrono
    University of Rome La Sapienza, Rome, Italy
    J Thromb Haemost 1:1710-3. 2003
  17. ncbi request reprint Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus
    Francesca Santilli
    Center of Excellence on Aging and Department of Medicine, University of Chieti G d Annunzio Schools of Medicine and Pharmacy, Chieti, Italy
    J Am Coll Cardiol 47:391-7. 2006
    ....
  18. ncbi request reprint Determinants of platelet activation in Alzheimer's disease
    Giovanni Ciabattoni
    Center of Excellence on Aging, G d Annunzio University Foundation, Italy
    Neurobiol Aging 28:336-42. 2007
    ..To investigate the rate of platelet thromboxane (TX) biosynthesis and its determinants in Alzheimer's disease...
  19. ncbi request reprint Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies
    Raffaele Landolfi
    Institute of Internal Medicine and Geriatrics, Catholic Uinversity School of Medicine, Rome, Italy
    Semin Thromb Hemost 32:251-9. 2006
    ..Future studies should assess primarily the efficacy and safety of aspirin in essential thrombocythemia, and test the possible use of more aggressive antithrombotic strategies in high-risk polycythemic patients...
  20. pmc Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials
    Patricia M Kearney
    Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford OX3 7LF
    BMJ 332:1302-8. 2006
    ..To assess the effects of selective cyclo-oxygenase-2 (COX 2) inhibitors and traditional non-steroidal anti-inflammatory drugs (NSAIDs) on the risk of vascular events...
  21. ncbi request reprint Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease
    Giulia Renda
    Departments of Medicine and Clinical Sciences, Center of Excellence on Aging, G D Annunzio University, School of Medicine, Chiete, Italy
    Clin Pharmacol Ther 80:264-74. 2006
    ....
  22. ncbi request reprint Drug insight: aspirin resistance--fact or fashion?
    Carlo Patrono
    University of Rome La Sapienza, Ospedale Sant Andrea, Via di Grottarossa 1035, 00189 Rome, Italy
    Nat Clin Pract Cardiovasc Med 4:42-50. 2007
    ..Gaining such knowledge could result in improved care of patients and might avoid the requesting of unnecessary platelet function tests of unproven clinical significance...
  23. ncbi request reprint Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal
    Colin Baigent
    Clinical Trial Service Unit, Radcliffe Infirmary, Oxford, UK
    Arthritis Rheum 48:12-20. 2003
  24. ncbi request reprint Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
    Roberto Marchioli
    European Collaboration on Low Dose Aspirin in Polycythemia Vera Coordinating Centre, Consorzio Mario Negri Sud, Via Nazionale, 66030 Santa Maria Imbaro, Italy
    J Clin Oncol 23:2224-32. 2005
    ..The aim of this study was to assess the rate of these complications in subjects receiving currently recommended treatments...
  25. ncbi request reprint Efficacy and safety of aspirin in the long-term management of atherothrombosis
    Carlo Patrono
    Haematologica 87:6-8. 2002
  26. pmc Antiplatelet drugs
    Gustav Born
    William Harvey Research Institute, St Bartholomew s and the Royal London School of Medicine and Dentistry, University of London, London
    Br J Pharmacol 147:S241-51. 2006
  27. ncbi request reprint Low-dose aspirin for the prevention of atherothrombosis
    Carlo Patrono
    Department of Pharmacology, University of Rome La Sapienza, Rome, Italy
    N Engl J Med 353:2373-83. 2005
  28. ncbi request reprint Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study
    Guido Finazzi
    Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy
    Blood 105:2664-70. 2005
    ..84-16.25; P = .0023), but not to hydroxyurea (HU) alone (HR, 0.86; 95% CI, 0.26-2.88; P = .8021), had an independent role in producing an excess risk for progression to AML/MDS compared with treatment with phlebotomy or interferon...
  29. ncbi request reprint Efficacy and safety of low-dose aspirin in polycythemia vera
    Raffaele Landolfi
    Catholic University School of Medicine, Rome, Italy
    N Engl J Med 350:114-24. 2004
    ..The use of aspirin for the prevention of thrombotic complications in polycythemia vera is controversial...
  30. ncbi request reprint Isoprostane formation and inhibition in atherothrombosis
    Carlo Patrono
    Department of Pharmacology, Universita di Roma La Sapienza, Ospedale Sant Andrea, Via di Grottarossa 1035, 00189 Rome, Italy
    Curr Opin Pharmacol 5:198-203. 2005
    ..Clinical studies support the hypothesis that enhanced lipid peroxidation may contribute, at least in part, to persistent platelet activation...
  31. ncbi request reprint Determinants of F2-isoprostane biosynthesis and inhibition in man
    Giovanni Davi
    Center of Excellence on Aging, School of Medicine, University of Chieti G D Annunzio, Via Colle dell Ara, 66013 Chieti, Italy
    Chem Phys Lipids 128:149-63. 2004
    ..This information could be extremely valuable in the selection of the appropriate patient subgroups that may benefit from antioxidant interventions...
  32. ncbi request reprint Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease
    Pietro Minuz
    Department of Biomedical and Surgical Sciences, University of Verona, Italy
    Circulation 106:2800-5. 2002
    ..Hypertensive patients with renovascular disease (RVD) may be exposed to increased oxidative stress, possibly related to activation of the renin-angiotensin system...
  33. ncbi request reprint Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology
    Carlo Patrono
    ESC Task Force on Antiplatelets, University of Rome La Sapienza, II Facolta di Medicina e Chirurgia, Via di Grottarossa, 1035, 00189 Roma, Italy
    Eur Heart J 25:166-81. 2004
  34. ncbi request reprint Platelet activation in obese women: role of inflammation and oxidant stress
    Giovanni Davi
    Center of Excellence on Aging, G D Annunzio University Schools of Medicine and Pharmacy, Chieti, Italy
    JAMA 288:2008-14. 2002
    ..Obesity, in particular abdominal adiposity, is associated with increased cardiovascular morbidity and mortality through mechanisms possibly linking the metabolic disorder to platelet and vascular abnormalities...
  35. ncbi request reprint Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues
    Michael J Thun
    Department of Epidemiology and Surveillance Research, American Cancer Society, National Home Office, Atlanta, GA 30329 4251, USA
    J Natl Cancer Inst 94:252-66. 2002
    ..Finally, we suggest research opportunities that may help to accelerate the future clinical application of NSAIDs for cancer prevention or treatment...
  36. ncbi request reprint Determinants of platelet activation in human essential hypertension
    Pietro Minuz
    Department of Biomedical and Surgical Sciences, University of Verona, Verona, Italy
    Hypertension 43:64-70. 2004
    ..These findings might help identify hypertensive patients who are at increased risk of cardiovascular events and who might benefit from long-term antiplatelet therapy...
  37. doi request reprint Guest authorship, mortality reporting, and integrity in rofecoxib studies
    Carlo Patrono
    JAMA 300:901; author reply 904-5. 2008
  38. ncbi request reprint Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration
    Giovanni Davi
    Center of Excellence on Aging and Department of Medicine, University of Chieti G d Annunzio Schools of Medicine and Pharmacy, Chieti, Italy
    Circulation 107:3199-203. 2003
    ..We also investigated the relationship between inflammatory markers and F2-isoprostane formation in this setting...
  39. ncbi request reprint Cyclooxygenase-2 polymorphism: putting a brake on the inflammatory response to vascular injury?
    Francesco Cipollone
    Arterioscler Thromb Vasc Biol 22:1516-8. 2002
  40. ncbi request reprint Platelet activation and atherothrombosis
    Giovanni Davi
    Center of Excellence on Aging, G d Annunzio University Foundation, Chieti, Italy
    N Engl J Med 357:2482-94. 2007
  41. ncbi request reprint Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects
    Marta L Capone
    Department of Medicine and Center of Excellence on Aging, G D Annunzio University, School of Medicine, and G d Annunzio University Foundation, Chieti, Italy
    Circulation 109:1468-71. 2004
    ..The current controversy on the potential cardioprotective effect of naproxen prompted us to evaluate the extent and duration of platelet, monocyte, and vascular cyclooxygenase (COX) inhibition by naproxen compared with low-dose aspirin...
  42. ncbi request reprint Insulin resistance as a determinant of platelet activation in obese women
    Stefania Basili
    Department of Medical Therapy, University of Rome La Sapienza, Rome, Italy
    J Am Coll Cardiol 48:2531-8. 2006
    ..We tested the hypothesis that insulin resistance, per se, contributes to increased platelet activation in obesity, independently of underlying inflammation...
  43. ncbi request reprint The PGH-synthase system and isozyme-selective inhibition
    Carlo Patrono
    Department of Pharmacology, University of Rome La Sapienza, Rome, Italy
    J Cardiovasc Pharmacol 47:S1-6. 2006
    ....
  44. ncbi request reprint [Expert consensus document on the use of antiplatelet agents]
    Carlo Patrono
    Rev Esp Cardiol 57:963-80. 2004
  45. ncbi request reprint Helicobacter pylori infection causes persistent platelet activation in vivo through enhanced lipid peroxidation
    Giovanni Davi
    Center of Excellence on Aging, Fondazione Universita G D Annunzio, Chieti, Italy
    Arterioscler Thromb Vasc Biol 25:246-51. 2005
    ....
  46. ncbi request reprint Lipid peroxidation in diabetes mellitus
    Giovanni Davi
    Center of Excellence on Aging, University of Chieti G D Annunzio School of Medicine, Chieti, Italy
    Antioxid Redox Signal 7:256-68. 2005
    ..e., isoprostanes), and the association between isoprostane formation and platelet activation. Finally, possible targets of antioxidant therapy for diabetic vascular complications will be discussed...
  47. ncbi request reprint Cyclooxygenase-2 expression and inhibition in atherothrombosis
    Francesco Cipollone
    Center of Excellence on Aging, G D Annunzio University of Chieti School of Medicine, Chieti, Italy
    Arterioscler Thromb Vasc Biol 24:246-55. 2004
    ....